Bioequivalence of Tipranavir Oral Solutions in Healthy Volunteers

Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of drug in plasma over the time interval from 0 extrapolated to infinity for tipranavir up to 72 hours and Maximum measured concentration of drug in plasma for tipranavir up to 72 hours. Started Apr 2008; status: completed.